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Differential effects of insulin-like growth factor binding pro- Impairment of longitudinal growth is a severe second-
teins-1, -2, -3, and -6 on cultured growth plate chondrocytes. ary complication of chronic renal failure (CRF) in child-
Background. In children with chronic renal failure (CRF), hood, which results in part from an altered growth hor-impairment of longitudinal growth is in part due to excess
mone (GH)/insulin-like growth factor (IGF)-I axis thatamounts of circulating high-affinity insulin-like growth factor
binding proteins (IGFBPs) that might decrease or prevent controls growth plate cartilage proliferation and hyper-
insulin-like growth factor (IGF) binding to its signaling recep- trophy [1, 2]. While immunoreactive GH and IGF levels
tor. However, it appears from the clinical studies that various are usually not decreased in CRF serum, the bioactiv-IGFBPs may have contrasting effects on longitudinal growth.
ity of IGFs is reduced due to excess amounts of circu-Because of the potential importance of the IGFBPs as mod-
ulators of longitudinal growth in pediatric CRF, the aim of lating high-affinity IGF binding proteins (IGFBPs) that
the present study was to investigate the biological effects of decrease or prevent IGF binding to its signaling recep-
IGFBP-1, -2, -3, and -6 on cultured growth plate chondrocytes tor [1–3].that express the type 1 IGF receptor.
Serum levels of intact IGFBP-1, IGFBP-2, IGFBP-4,Methods. The effects of exogenous IGFBPs on IGF-inde-
pendent and IGF-dependent proliferation of rat growth plate IGFBP-6 and low molecular weight fragments of IGFBP-3
chondrocytes in primary culture were investigated. Prolifera- are elevated in CRF serum in relation to the degree of re-
tion was assessed by colony formation of agarose-stabilized nal dysfunction, whereas serum levels of intact IGFBP-3long-term suspension cultures and by the [3H]thymidine assay.
are normal [3–13]. Immunoreactive IGFBP-5 levels areThe effects of IGFBPs on IGF-I binding and the binding of
IGFBPs to chondrocytes were assessed by binding studies with not altered in CRF serum, but the majority of IGFBP-5
radiolabeled proteins in monolayer culture. is fragmented [11, 12]. Previous clinical studies in chil-
Results. Intact IGFBP-1, IGFBP-2 and IGFBP-6 inhibited dren with CRF suggested by correlation analyses ofin equimolar concentration the IGF-I- and IGF-II-stimulated
IGFBP serum levels with growth parameters that partic-DNA synthesis and cell proliferation, whereas the biological
activity of IGFBP-3 was complex. It had an IGF-independent ularly excess IGFBP-1, IGFBP-2, and IGFBP-4 may
antiproliferative effect and also inhibited IGF-dependent chon- function as growth inhibitors in uremic children [4, 10,
drocyte proliferation under coincubation conditions, whereas 11]. The potential role of serum IGFBP-3 for longitudi-under preincubation conditions IGFBP-3 enhanced IGF-I-
nal growth appears to be more complex. Our previousresponsiveness. Studies on the mechanism by which IGFBP-3
potentiated IGF activity demonstrated that under preincuba- study found no positive relationship between immunore-
tion conditions IGFBP-3 is capable to associate with the cell active IGFBP-3 and standardized height in CRF [4], as
membrane and to facilitate IGF-I cell surface binding. observed under normal conditions in healthy childrenConclusions. Intact IGFBP-1, IGFBP-2 and IGFBP-6 act ex-
[14], nor was there a negative correlation, which wouldclusively as growth inhibitors on IGF-dependent proliferation
of growth plate chondrocytes. IGFBP-3, however, can either be expected if IGFBP-3 acted merely as an IGF inhibitor
inhibit IGF-independent and IGF-dependent cell proliferation, in CRF. On the other hand, GH therapy in CRF induced
or enhance IGF responsiveness of chondrocytes dependent on an increase in serum IGFBP-3 levels in correlation tothe temporal relationship to the IGF exposure.
the improved growth of these children [10], suggesting
a potential growth stimulatory effect of intact IGFBP-3
Key words: IGF, longitudinal growth failure, cartilage growth, pediatric
in this setting. The IGF/IGFBP system also appears tochronic renal failure, childhood growth, signaling receptor, cell prolifer-
ation. play a role in the pathogenesis of renal osteodystrophy.
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stimulatory IGF system components (IGF-I, IGF-II,and in revised form April 29, 2002
Accepted for publication June 11, 2002 IGFBP-5) showed positive correlations with histologic
parameters of bone formation, whereas the serum levels 2002 by the International Society of Nephrology
1591
Kiepe et al: IGFBP action in growth plate chondrocytes1592
of inhibitory IGFBPs (IGFBP-2 and IGFBP-4) showed purified by reverse-phase HPLC, as described previously
for human IGFBP-3 [24]. Recombinant human IGFBP-3positive correlations with histologic indices of bone
loss [13]. was expressed in CHO-K1 cells (Genentech Inc., South
San Francisco, CA, USA) or baculovirus (BV)-transfectedWhile it appears from the clinical studies that various
IGFBPs may have contrasting effects on longitudinal insect cells [25]. Recombinant human IGFBP-6 was ex-
pressed in Sf21 insect cells as follows: The cDNA encod-growth in uremic children, only one comparative study
in vitro has been conducted to delineate their respective ing human IGFBP-6 [26], kindly provided by Dr. Michael
Kiefer (Chiron Corp., Emeryville, CA, USA), was sub-roles in cartilage growth. We have shown previously that
intact IGFBP-4 and, to a lesser extent, the amino-termi- cloned into the M13-based vector M13mp18 at the EcoRI
site. After a BamHI site was introduced into the 5 codingnal fragment IGFBP-41-122 act exclusively as growth inhib-
iting binding proteins in the growth cartilage. IGFBP-5, region of the IGFBP-6 cDNA using the Muta-Gene kit
(BioRad, Richmond, CA, USA) as described previouslyon the other hand, can either stimulate, if it remains in-
tact, or inhibit IGF-I-stimulated chondrocyte proliferation [25], the BamHI (5)-EcoRI (3) IGFBP-6 cDNA frag-
ment was subcloned into the pAcGP67 transfer vectorif amino-terminal fragments predominate [15]. IGFBP-1,
-2, -3, and -6 have been shown to inhibit IGF actions in (PharMingen, San Diego, CA, USA). The transfer vec-
tor was then recombined with Baculogold DNA; in themost cell culture systems, but stimulatory effects also have
been established for IGFBP-1, -2, and -3 [16]. In particu- resulting recombinant baculovirus, the polyhedrin pro-
moter drives expression of the signal peptide from thelar, IGFBP-3, by far the most abundant IGFBP in the
circulation, appears to play a complex role in the cellular secreted baculovirus glycoprotein gp67 fused to the full-
length circulating form of the IGFBP-6 protein. Produc-environment. It can be a potent inhibitor of cell growth
by virtue of its ability to bind IGF with high affinity, tion, amplification and isolation of recombinant baculo-
virus, and baculovirus infection of Sf21 insect cells, werethereby preventing its interaction with membrane recep-
tors [17–19]. IGFBP-3 also can function as a direct cell performed as described previously for recombinant hu-
man IGFBP-3 [25]. Purified IGFBP-6 was obtained bygrowth inhibitor, independent of its IGF binding activity
[20]. Furthermore, IGFBP-3 can potentiate IGF action increasing [NaCl] to 2.5 mol/L in media conditioned
by IGFBP-6-expressing Sf21 cells, passing this across anin a number of cell systems [16]. IGFBP-6 is a relatively
specific inhibitor of IGF-II actions; it has not been shown IGF-II affinity column, and then eluting IGFBP-6 from
the column in 1% acetic acid. The C-terminal IGFBP-5to potentiate IGF actions and its expression is associated
with inhibition of growth of tumor cells in vitro and in fragment IGFBP-5144-252 was purified from hemofiltrate
of end-stage renal failure patients as described previ-vivo [21].
Because of the potential importance of IGFBPs as ously [27].
Recombinant human IGF-I and IGF-II were pur-modulators of longitudinal growth in pediatric chronic
renal failure, the aim of the present study was to investi- chased from Bachem (Heidelberg, Germany); des(1-3)-
IGF-I was obtained from GroPep (Adelaide, Australia).gate the biological effects of IGFBP-1, -2, -3, and -6
on cultured growth plate chondrocytes that express the [3H]thymidine (25 Ci/mmol) and [125I]-IGF-I (2000 Ci/
mmol of protein) were obtained from Amersham Phar-type 1 IGF receptor [22]. Furthermore, we sought to
identify the mechanisms by which IGFBP-3 exerts both macia Biotech (Buckinghamshire, UK). Radioiodination
of the IGFBPs (20 to 100 Ci/g of protein) was per-its stimulatory and inhibitory action on growth plate
chondrocytes. formed using a standard chloramine T method: Two
micrograms of each peptide were dissolved in 75 L 0.25
mol/L sodium phosphate, pH 7.5 and Na125I (0.2 mCi;
METHODS
Amersham, Braunschweig, Germany) and 10 L chlora-
Materials mine-T (2.5 mg/mL in phosphate buffer) were added.
After incubation for 60 seconds, the reaction was stoppedInsulin-like growth factor binding protein-1 was iso-
lated from human amniotic fluid through an IGF-I affin- by the addition of 10 L Na2S2O5 (3.2 mg/mL in phos-
phate buffer). Each radiolabeled peptide was purifiedity column as described previously [23]. Bovine IGFBP-2
was isolated from Madin-Darby bovine kidney (MDBK) on Sep-Pak C18 cartridges (Waters-Millipore, Eschborn,
Germany). After application of the iodinated sample thecells (ATCC, Rockville, MD, USA) as follows: MDBK
cells, grown and maintained in Dulbecco’s modified Ea- cartridge was rinsed with 5 mL 10 mmol/L HCl to remove
unbound material. Elution was carried out using 1 mLgle’s medium (DMEM) containing 10% fetal bovine se-
rum (FBS) and 1% penicillin/streptomycin, were incu- 80% acetonitrile in 10 mmol/L HCl. The homogeneity
and the specific activity of the radiolabeled peptide wasbated in serum-free medium for 72 hours. Conditioned
medium was then collected, brought to 2.5 mol/L NaCl controlled on the high pressure liquid chromatography
(HPLC) system 322 (Kontron, Neufahrn, Germany) byand passed through an IGF-I affinity column. Bovine
IGFBP-2 was eluted from the IGF-I column, and further separation on an analytical RP-C18 column using a linear
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acetonitrile gradient with on-line detection of the ab- in trichloroacetic acid-precipitable material as described
sorbance at 214 nm and of the radioactivity using the previously [15, 22]. Prior to the experiment, cells were
-measuring cell J-1000 (Berthold, Wildbad, Germany). synchronized in cell cycle by starving in serum-free F-12/
Standard low and low gel temperature (LGT) agarose DMEM for 24 hours. Medium was changed to F-12/
was purchased from BioRad; FCS, PBS, HEPES, peni- DMEM with 0.2% BSA, and hormones or solvents were
cillin-streptomycin, Ham’s F-12 and DMEM were ob- added as indicated for 48 hours. For the last 4 hours, cul-
tained from Seromed Biochrom KG (Berlin, Germany). tures were coincubated with 2 Ci of [3H]thymidine. In
Bovine serum albumin (BSA) was purchased from Sigma- the preincubation experiments, cells were exposed for
Aldrich Chemicals (Deisenhofen, Germany). Clostridium the indicated time with the respective IGFBP at 37C
collagenase (EC 3.4.24.3), Deoxyribonuclease (DNAse I and washed three times with serum-free F-12/DMEM,
(EC 3.1.21.1) and trypan blue were from Roche Diagnos- followed by incubation with IGF-I for 24 hours. Subse-
tics GmbH (Mannheim, Germany). quently, cells were rinsed twice with phosphate-buffered
saline and extracted with sodium hydroxide (1 mol/L).
Cell cultures Before counting, the extract was mixed with scintilla-
Epiphyseal chondrocytes from 60 to 80 g Sprague- tion fluid.
Dawley rats (Charles River, Kieslegg, Germany) were
isolated and cultured as described previously [15, 22]. Effect of IGFBP-3 on [125I]-IGF-I binding to
Pooled growth plates from four to eight animals were chondrocytes in monolayer culture
digested with clostridial collagenase (0.12% wt/vol) and Binding studies were performed as described previ-
bacterial DNAse (0.02% wt/vol) in F-12 medium. Viabil- ously [15, 28]. Briefly, confluent chondrocytes were rinsed
ity, determined after isolation and at the end of each twice with serum-free F-12/DMEM medium containing
experiment by the trypan blue exclusion technique, al- 1% BSA, pH 7.4. In the co-incubation experiments, vari-
ways exceeded 90%. Dissociated cells were counted us- ous concentrations of IGFBPs were added and incubated
ing a Neubauer chamber (Scheik, Hofheim, Germany). with [125I]-IGF-I (10,000 cpm) in the absence or presence
Cells were cultured in monolayers in 96-well plates of unlabeled IGF-I (250 ng/mL) at 4C for three hours. In
for proliferation assays and in 24-well plates (Nunc, the pre-incubation experiments, cultures were incubated
Wiesbaden, Germany) for binding studies as described with IGFBP-3 at 37C for three hours followed by in-
previously [15, 22]. The F-12/DMEM (1:1) medium con- tensive washing with cold serum-free F-12/DMEM me-
tained a nominal calcium concentration of 1.2 mmol/L dium containing 1% BSA, pH 7.4, and incubation with
and the medium was supplemented with 10 mmol/L
[125I]-IGF-I (10,000 cpm) in the absence or presenceHEPES, 100 g/mL streptomycin, and 10% FCS. In pre-
of unlabeled IGF-I (250 ng/mL) at 4C for three hours.vious studies using the same culture system, we demon-
Cultures were incubated with IGFBP-3 at 37C for threestrated that the majority of cells after the first passage
hours, because a shorter incubation time (2 hours) ofexpressed typical markers for proliferative growth plate
IGFBP-3 was associated with less binding (70%) of [125I]-chondrocytes. Peptide hormones were dissolved in PBS
IGF-I to chondrocytes, and a longer incubation time (24and added every day unless indicated otherwise.
hours) of IGFBP-3 did not further enhance [125I]-IGF-IFor the agarose-stabilized suspension cultures, cells
cell membrane binding. The labeled medium was dis-were cultured in agarose in 35-mm dishes (Nunc) as de-
carded, the cells were rinsed five times with serum-freescribed previously [15, 22]. One milliliter of F-12/DMEM
F-12/DMEM medium and extracted with sodium hy-containing 0.2% BSA, 0.1% FCS, and hormones or sol-
droxide. Cell-surface associated [125I]-IGF-I was deter-vents as indicated was added to the cell suspension
mined by counting the cell lysates in a -counter. Specific(40,000 cells/mL in 0.5% low gel temperature agarose).
binding was calculated as the difference between bindingMedium was changed every second day, and cells were
in the absence and presence of excess cold IGF-I (250cultured for two weeks. Cultures were screened for clus-
ng/mL). The non-specific binding was consistently 7%.ters of more than three cells. No such clusters were seen
at the start of culture in any experiment. Suspension
[125I]-IGFBP-3 binding to chondrocytescultures were terminated after 12 days by fixation in
For binding studies, confluent cells were rinsed twice4% buffered formaldehyde and methanol. Colonies were
with serum-free F-12/DMEM medium, as described pre-counted under the microscope in 100 squares (2 mm-
viously [15, 28]. Each well was incubated with 250 Lgrid) for each dish. A cell colony was defined as a cluster
medium and with the respective [125I]-IGFBP-3 (80,000of three or more cells with matrix stained by alcian blue
cpm) or vehicle in the absence or presence of varyingas previously described [15, 22].
concentrations of the respective unlabeled IGFBP at 4C
[3H]thymidine assay for three hours. At the end of the incubation period, the
labeled medium was discarded, and the cells were rinsedIncorporation of [3H]thymidine into DNA was deter-
mined in 96-well plate cultures as uptake of radioactivity five times with serum-free F-12/DMEM medium. [125I]-
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Fig. 1. Effects of IGFBP-1 (7.8 nmol/L),
IGFBP-6 (7.8 nmol/L) (A) or IGFBP-2 (B)
on IGF-I (7.8 nmol/L)-stimulated colony for-
mation in agarose-stabilized suspension cul-
ture. After 12 days of incubation, the cultures
were terminated by fixation in buffered form-
aldehyde (4%). The colonies were counted in
100 squares (2-mm grid) with an inverted light
microscope. Values present the mean of 8
dishes  SE. Statistics (pertain to endpoints)
by ANOVA. *P  0.05 vs. control; #P  0.05
vs. IGF-I.
Table 1. Effects of insulin-like growth factors on basal and IGF-I–stimulated DNA synthesis, as assessed by [3H]thymidine incorporation
IGFBP 7.8 nmol/L IGF-I 7.8 nmol/L IGF-I  IGFBP 1:1 IGF-I  IGFBP 1:2
IGFBP Control
added % % of control
IGFBP-1 1004.3 1253.9 19815.0a 1388.0a 1334.6b
IGFBP-2 1006.7 1155.7 1737.8a 1384.5 1306.7b
IGFBP-3BV 1006.2 1025.4 1729.5a 1405.4ab 1377.0ab
IGFBP-6 1004.6 1099.3 1917.7a 1156.0b ND
Subconfluent chondrocytes were cultured in serum-free medium for 24 hours. Medium was changed to F-12/DMEM containing 0.2% BSA, and peptides or vehicle
were added for 48 hours as indicated. [3H]thymidine incorporation was determined as described in the Methods section. [3H]thymidine incorporation in control
cultures was 598  63.5 cpm (range, 417 to 814 cpm). Data are the mean  SE expressed as the percent of control. Abbreviations are: IGFBP, insulin-like growth
factor binding factor; BSA, bovine serum albumin; ND, not done. Statistics are by ANOVA of 9 to 12 parallel dishes per group.
a P  0.05 vs. control
b P  0.05 vs. IGF-I
IGFBP-3 bound to cells was extracted with lysis buffer of cells with IGF-I and IGFBP-1 in equimolar concentra-
and counted as described previously [15, 28]. tions (7.8 nmol/L) reduced the IGF-I-driven prolifera-
tion by 85% (Fig. 1). A comparably inhibitory effect of
Statistics intact IGFBP-1 on the IGF-I-stimulated (Table 1) and
IGF-II-stimulated DNA synthesis (Table 2), as measuredData are given as mean SE. All data were examined
for normal and non-Gaussian distribution by the Kolmo- by the [3H]thymidine incorporation assay, was observed.
IGFBP-2 and IGFBP-6 inhibited IGF-I–stimulated cellgorov-Smirnov test. For comparison among normally dis-
tributed groups, one-way ANOVA followed by pairwise proliferation (Fig. 1) and IGF-I- or IGF-II–driven DNA
synthesis (Tables 1 and 2) to a similar extent.multiple comparison (Student-Newman-Keuls method)
was used. For non-normally distributed data, the non- To demonstrate that the inhibitory action of the re-
spective IGFBPs on IGF-stimulated cell proliferationparametric Kruskal-Wallis test followed by an all pair-
wise multiple comparison (Dunnett’s method) was used. are not IGF-independent, we analyzed the effect of the
IGF variant des(1-3)-IGF-I, which has a 100-fold re-P  0.05 was considered statistically significant.
duced affinity for these IGFBPs, but a similar binding
affinity as IGF-I to the type 1 IGF receptor [29]. IGFBP-1,
RESULTS IGFBP-2, and IGFBP-6 had no effect on stimulation of
Effects of IGFBP-1, IGFBP-2 and IGFBP-6 on DNA synthesis in response to des(1-3)-IGF-I (Fig. 2).
IGF-stimulated growth plate chondrocyte proliferation
Effects of IGFBP-3 on growth plateThe maximally effective concentration of IGF-I on
chondrocyte proliferationcolony formation in agarose-stabilized suspension cul-
Under baseline conditions in the absence of exogen-tures was 60 ng/mL (7.8 nmol/L). This IGF-I-induced
ous IGF-I, both IGFBP-3CHO and IGFBP-3BV, but notcell proliferation corresponded to approximately 50% of
IGFBP-2, had an antiproliferative effect on colony for-the maximally achievable cell proliferation by incubation
mation in the agarose-stabilized suspension culture sys-with FCS 10% (data not shown). The IGF-I–stimulated
tem (Fig. 3A). IGFBP-3 did not decrease basal DNAcolony formation was decreased when chondrocytes were
exposed to intact IGFBP-1. The simultaneous exposure synthesis in the absence of exogenous IGF-I (Table 1)
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Table 2. Effects of IGFBPs on basal and IGF-II–stimulated DNA synthesis, as assessed by [3H]thymidine incorporation
IGFBP 7.8 nmol/L IGF-II 7.8 nmol/L IGF-II  IGFBP 1:1 IGF-II  IGFBP 1:2
IGFBP Control
added % % of control
IGFBP-1 1005.2 1123.5 1567.5a 95.03.0b ND
IGFBP-2 1001.7 99.02.0 1752.9a 1212.7b ND
IGFBP-3BV 1006.2 1025.4 1729.5a 1405.4ab 1377.0ab
IGFBP-6 1005.6 98.07.0 1678.5a 96.05.0b 99.510.0b
Subconfluent chondrocytes were cultured in serum-free medium for 24 hours. Medium was changed to F-12/DMEM containing 0.2% BSA, and peptides or vehicle
were added for 48 hours as indicated. [3H]thymidine incorporation was determined as described in the Methods section. [3H]thymidine incorporation in control
cultures was 598  42.5 cpm (range, 503 to 1024 cpm). Data are the mean  SE expressed as the percent of control. Abbreviations are in Table 1. Statistics are by
ANOVA of 9 to 12 parallel dishes per group.
a P  0.05 vs. control
b P  0.05 vs. IGF-II
Because IGFBP-3 can potentiate IGF action in a num-
ber of cell systems [18] and it had been shown using a
bovine fibroblast model that this ability to stimulate cell
growth requires IGFBP-3 cell-association [30, 31], we
investigated the effect of IGFBP-3 on IGF-I-stimulated
DNA synthesis under pre-incubation conditions. Rat
growth plate chondrocytes were pre-incubated for 24
hours with IGFBP-3 in the absence of IGF-I followed by
extensive washing. IGFBP-3 (10 nmol/L) pre-exposure
potentiated the IGF-I–stimulated [3H]thymidine uptake
(Fig. 4A). A longer pre-incubation period (48 hours) did
not modify the potentiating effect of IGFBP-3 on IGF-I
action (results not shown). Pre-incubation with IGFBP-2
did not alter IGF-I–stimulated DNA synthesis under
identical experimental conditions (Fig. 4B).
IGFBP-3 effects on binding of IGF-I to growth plate
Fig. 2. Effects of IGFBP-1, IGFBP-2, IGFBP-3CHO or IGFBP-6 (all
chondrocytes and IGFBP-3 cell membrane binding7.8 nmol/L) on des(1-3)-IGF-I (7.8 nmol/L)-stimulated DNA synthesis
in the thymidine incorporation assay. Subconfluent chondrocytes were From these data we hypothesized that IGFBP-3 modu-
cultured in serum-free medium for 24 hours. Medium was changed to
lates IGF-I action on chondrocytes by differentially af-F-12/DMEM containing 0.2% BSA, and peptides or vehicle was added
for 48 hours as indicated. [3H]thymidine incorporation was determined fecting the binding of IGF-I to its receptor. To examine
as described in the Methods section. [3H]thymidine incorporation in this hypothesis, the effect of IGFBP-3 on [125I]-IGF-I bind-
control cultures was 342  27.4 cpm (range, 216 to 450 cpm). Data
ing to the cell surface of chondrocytes was investigated.are the mean  SE expressed as the percent of control. Statistics by
ANOVA of 9 to 12 parallel dishes per group. *P  0.05 vs. control, When these cell binding assays were performed under
#P  0.05 vs. des(1-3)-IGF-I. co-incubation conditions of IGFBP-3BV and tracer, intact
IGFBP-3 led to a dose-dependent reduction of labeled
IGF-I binding to the cell membrane, presumably because
soluble IGFBP-3 in the cell medium has a higher affinityor IGF-II (Table 2), presumably because incubation with
to labeled IGF-I than membrane-bound IGFBP-3, therebyserum-free medium prior to addition of IGFBP-3 de-
overriding the effect of membrane-bound IGFBP-3 oncreased basal levels of [3H]thymidine incorporation to
IGF-I tracer binding to the cell membrane (Fig. 5A).an extent from which further inhibition could not be
To test the hypothesis that membrane-bound IGFBP-3detected. In support of this hypothesis, IGFBP-3 was
affects IGF-I tracer binding to the cell membrane, weable to inhibit the DNA synthesis stimulated by des(1-3)-
modified the experimental conditions and pre-incubatedIGF-I, which has negligible affinity for IGFBP-3; this
the cells in monolayer culture with IGFBP-3 for threesuggests that the antiproliferative effect is IGF-indepen-
hours to allow potential cell membrane binding, followeddent (Fig. 2). The simultaneous exposure of cells with
by extensive washing. Under these experimental condi-IGF-I and IGFBP-3 in equimolar concentrations re-
tions, IGFBP-3 led to a dose-dependent increase in theduced the IGF-I-stimulated colony formation by 45 to
binding of labeled IGF-I to chondrocytes (Fig. 5B).60% (Fig. 3B). The IGF-I- or IGF-II–driven DNA syn-
Next, we sought to determine whether the enhancedthesis was reduced by IGFBP-3 to a comparable extent
(Tables 1 and 2). binding of IGF-I to the cell membrane in the presence
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Fig. 3. Inhibitory effects of IGFBP-3 on ba-
sal or on IGF-I-stimulated colony formation
in agarose-stabilized suspension culture. (A)
The antiproliferative effect of IGFBP-3CHO or
IGFBP-3BV (7.8 nmol/L) compared to IGFBP-2
(7.8 mol/L) on basal colony formation. (B) The
inhibitory effects of IGFBP-3CHO or IGFBP-3BV
(7.8 nmol/L) on IGF-I (7.8 nmol/L)-stimulated
colony formation. Methods and statistics are in
Figure 1. Values present the mean of 8 dishes
SE. *P  0.05 vs. control; #P  0.05 vs. IGF-I.
Fig. 4. Effects of preincubation with the
indicated concentrations of IGFBP-3 (A) or
IGFBP-2 (B) on IGF-I–driven [3H]thymi-
dine incorporation. Cells were exposed with
IGFBP-3BV or IGFBP-2 for 24 hours at 37C,
followed by washing three times with serum-
free F12/DMEM, as described in the Methods
section. Subsequently, cells were incubated
with IGF-I for 24 hours and for the last four
hours, 2 Ci of [3H]thymidine was added to
determine the [3H]thymidine incorporation.
Statistics by ANOVA for 6 (A) and 8 (B) paral-
lel the wells per group. *P  0.05 vs. control;
#P  0.05 vs. preincubation without IGFBP-3.
Fig. 5. Effects of added IGFBP-3BV on the
binding of [125I]-IGF-I to chondrocytes under
coincubation (A) or preincubation (B) condi-
tions. Cells in monolayer culture were incu-
bated with IGFBP-3 of varying concentra-
tions at 4C for 3 hours. For the experiments
under preincubation conditions, the cells were
washed twice prior to incubation with [125I]-
IGF-I (10,000 cpm) at 4C for 3 hours. Data are
the mean of three replicate determinations of
two experiments expressed as the percent of
the specific [125I]-IGF-I binding in the absence
of exogenous IGFBP-3. Control cpm deter-
mined in the absence of IGFBP-3 was 896 
41. *P  0.05 vs. [125I]-IGF-I binding in the
absence of exogenous IGFBP-3.
of IGFBP-3 is mediated by direct binding of IGFBP-3 DISCUSSION
to the cell membrane. In serum-free monolayer culture, The present study demonstrates that intact IGFBP-1,
there was a specific binding of labeled IGFBP-3 to cells IGFBP-2 and IGFBP-6 have an exclusively inhibitory
that was affected by added unlabeled IGFBP-3, but not action on IGF-I–stimulated cell proliferation in long-
by added unlabeled IGFBP-5144-252 that also is capable to term cultures of growth plate chondrocytes and on
IGF-I- or IGF-II–driven DNA synthesis. Our findingbind to chondrocyte (Fig. 6) [15].
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above findings, serum levels of intact IGFBP-1 and -2
correlate significantly and inversely with standardized
height in CRF children implying that these two IGFBPs
contribute to the growth failure in these children [4, 10].
We observed an inhibitory effect of IGFBP-6 on
IGF-I- and IGF-II–mediated DNA synthesis and IGF-I–
stimulated colony formation in cultured chondrocytes.
Although IGFBP-6 has a preferential affinity for IGF-II
[39], the inhibitory effect of IGFBP-6 on the activity of
IGF-I and IGF-II in this cell culture system was compara-
ble. Enhanced expression of IGFBP-6 is associated with
inhibition of growth of tumor cells in vitro and in vivo;
IGFBP-6 has not been shown to potentiate IGF actions
on other cell culture systems [21]. To date no IGFBP-6
transgenic mouse model exists. In serum of children with
CRF, there was a marked (5- to 15-fold) elevation of
intact IGFBP-6 levels [6], and on a molar level, IGFBP-6
is the second most abundant serum IGFBP in childrenFig. 6. Binding of [125I]-IGFBP-3BV to chondrocytes in monolayer cul-
with end-stage renal disease [6, 11]. These data suggestture. Cells were incubated with IGFBP-3 of varying concentrations at
4C for 3 hours as described in the Methods section. Cells were incubated that IGFBP-6 likely interferes with IGF-mediated growth
either with intact [125I]-IGFBP-3 (80,000 cpm) or vehicle in the absence of cartilage and bone in children with CRF.or presence of varying concentrations of unlabeled IGFBP-3 (solid
The effects of IGFBP-3 on cultured growth plate chon-line) or IGFBP-5144-252 (dashed line) at 4C for 3 hours. Control cpm
determined in the absence of unlabeled IGFBP-3 were 5218  270 drocytes in this study were complex. Both preparations
(N 	 6). Data are the mean  SE of three replicates of two different of intact IGFBP-3 had an antiproliferative effect on col-experiments expressed as the percent of the binding observed without
ony formation in the agarose-stabilized suspension cul-added IGFBP. *P  0.05 vs. [125I]-IGFBP binding in the absence of
exogenous IGF ture system in the absence of exogenous IGFs. IGFBP-2
did not modify colony formation under identical experi-
mental conditions. IGFBP-3 also inhibited DNA synthe-
sis in response to des(1-3)-IGF-I, which has a markedlythat IGFBP-1 acts as an inhibitory IGFBP in growth
reduced affinity to IGFBP-3 [29]. These observationsplate chondrocytes is consistent with previous in vitro
indicate that IGFBP-3 has a direct antiproliferative effectobservations that IGFBP-1 inhibits the growth of chick
on chondrocytes that is independent of IGFs. A similar
embryo pelvic cartilage in a serum-free organ culture
growth inhibitory activity of IGFBP-3 in a mesenchymal
system [23]. Direct evidence now exists that IGFBP-1 chondrogenic cell line during the early stages of differen-
has the potential to impair longitudinal growth in vivo. tiation was recently reported [40]. Furthermore, IGFBP-3
Treatment of hypophysectomized rats with GH or IGF-I diminished the growth rate of mouse fibroblasts with a
stimulated weight gain and tibial epiphyseal widening, targeted disruption of the type 1 IGF receptor, suggest-
but co-injection with recombinant IGFBP-1 inhibited ing IGF-independent mechanisms [41]. Future studies
this growth in a dose-dependent manner [32]. In addi- are needed to determine whether this inhibitory effect
tion, transgenic mice overexpressing IGFBP-1 in multi- of IGFBP-3 on chondrocyte growth is only due to inhi-
ple tissues [33] or in liver alone [34] are also growth- bition of proliferation or also due to the induction of
retarded. apoptosis [42].
Our observation of an inhibitory effect of IGFBP-2 The modulatory effect of IGFBP-3 on IGF-I activity
on IGF-mediated chondrocyte proliferation is novel. In in cultured chondrocytes was dependent on its temporal
several other cell culture systems, either negative or posi- relationship to IGF-I. Co-incubation of IGFBP-3 with
tive effects have been observed [35]. The inhibiting activ- IGF-I in equimolar concentrations inhibited IGF-I medi-
ity of IGFBP-2 appears to be due to sequestration of ated colony formation, obviously by inhibition of IGF-I
IGFs, because it binds to the IGFs with a higher affinity binding to chondrocytes, thereby blocking receptor acti-
than the type 1 IGF receptor, whereas the stimulatory vation. In contrast, pre-incubation with IGFBP-3 en-
activity of IGFBP-2 in some tumor cell lines appears to hanced the responsiveness of chondrocytes to IGF-I,
be IGF-independent [36]. Direct evidence now exists because under these cell culture conditions, IGFBP-3
from experiments in transgenic mice that overexpressing stimulated the binding of IGF-I to the cell membrane.
IGFBP-2 is associated with reduced postnatal body This effect of IGFBP-3 appears to be due to its capability
weight gain [37] and inhibition of GH-stimulated growth to associate with the cell membrane. It has been specu-
lated that cell-associated IGFBP-3 is processed to a formin giant GH transgenic mice [38]. Consistent with the
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Table 3. Summary of IGBFs and their CRF plasma fragments
Effect on growth plate
chondrocyte proliferationa
Concentration Correlation to Growth in
IGFBP in CRF plasma growth in clinical CRF Intrinsic IGF-dependent transgenic animals
Intact IGFBP-1 increased [4, 10] negative [4] noneb ↓b pre-/postnatally reduced [33, 34]
Intact IGFBP-2 increased [4, 10] negative [4, 10] noneb ↓b postnatally reduced [35]
Intact IGFBP-3 normal [7, 10] nonec [4, 10] ↓b ↓/↑b,d pre-/postnatally reduced [45]
IGFBP-329 increased [8] ND nonee [8] ↓ (IGF-II)e [8]
Intact IGFBP-4 increased [11, 12] negative [11] none [15] ↓ [15] ND
IGFBP-41-122  [46] ND none [15] ↓ [15]
IGFBP-4136-237  [46] ND none [15] none [15]
Intact IGFBP-5 normalc [11, 12] positivec [11, 12] ↑ [15] ↑ [15] ND
IGFBP-51-169 ND ND none [15] ↓ [15]
IGFBP-5144-252  [27] ND none [15] none [15]
Intact IGFBP-6 increased [6] none [6] noneb ↓b ND
The concentration of intact IGFBPs and their respective fragments in CRF plasma, their correlation with parameters of longitudinal growth in children with CRF,
their intrinsic and IGF-dependent effects on growth plate chondrocyte proliferation and the effects of their respective overexpression on growth in transgenic animals
are shown. References are in brackets. Symbols are: , fragments present; ND, not done; ↓, inhibitory; ↑, stimulatory.
a Rat growth plate chondrocytes in primary culture
b Data from this article
c Immunoreactive IGFBP levels
d Dependent on cell culture conditions
e Human chondrosarcoma cells
of reduced affinity, which in some way enhances the pre- taneously: (a) synthesis of new bone from growth carti-
lage due to the process of endochondral ossification, andsentation of IGFs to the type 1 IGF receptor [43]. The
data presented here are more consistent with this mecha- (b) modeling-remodeling of previously synthesized bone
including primary and secondary spongiosa. In the pres-nism than with the more pronounced potentiation of
IGF-I action that results from IGFBP-3 signaling to PI-3- ent study, we focused on the effect of IGF/IGFBP system
components on cultured growth plate chondrocyte pro-kinase and PKB/akt in a pathway that is independent of
the type I IGF receptor [44]. In vivo overexpression of liferation as a model of the growth cartilage. The role
of the IGF/IGFBP system for chondrocyte differentia-IGFBP-3 in transgenic mice leads to a 4.9- to 7.7-fold
increase of serum IGFBP-3 levels and to modest intra- tion and for modeling-remodeling of previously synthe-
sized bone tissue in the context of renal failure will beuterine and postnatal growth retardation despite ele-
vated circulating IGF-I [45]. This suggests that, in vivo, a topic of future research.
Table 3 summarizes the findings of this and previ-the inhibitory effects of excess IGFBP-3 on chondrocyte
growth predominate over the modest growth-stimulatory ous studies on the effect of various IGFBPs and their
respective fragments from CRF plasma on growth plateeffects observed with IGFBP-3 preincubation.
Increased binding of IGFs by inhibitory IGFBPs might chondrocytes in culture compared to clinical studies on
IGFBP serum levels and growth in children with CRFbe compensated by an up-regulation of the type 1 IGF
receptor to overcome this inhibition, the net result being and observations in transgenic animals. From these data,
intact IGFBP-1, IGFBP-2 and IGFBP-4 clearly fulfill theno change in the biological response to the IGFs. In the
present study however, IGFBP-1, IGFBP-2, IGFBP-6, criteria of growth inhibitors both in vivo and in vitro,
whereas IGFBP-5 appears to act as a growth-stimulatoryand IGFBP-3 (under co-incubation conditions) clearly
inhibited the biological response of cultured chondro- IGFBP, and the role of IGFBP-3 is complex. The precise
characterization of the biological effects of inhibitorycytes to IGF-I. Hence, it is not likely that binding of
IGF-I to IGFBPs leads to a significant compensatory and stimulatory IGFBPs and their respective fragments
on IGF-mediated chondrocyte proliferation may haveup-regulation of the type 1 IGF receptor in chondrocytes
that would mitigate the inhibitory activity of some implications for new therapeutic strategies. Novel pep-
tides have recently been discovered, using phage dis-IGFBPs. In a previous series of experiments, incubation
of chondrocytes with IGFBP-5, IGF-I, or IGF-I plus played peptide libraries, which show remarkable spe-
cificity in binding to defined IGFBPs [47]. These peptidesIGFBP-5 was not associated with a significant change in
type 1 IGF receptor expression [15]. In a rat model have the potential to act as IGF displacers by both pre-
venting IGF-I binding to a specific inhibitory IGFBPof chronic renal failure, we are currently investigating
whether an excess of IGFBPs in serum and tissues in and displace IGF that is bound to this IGFBP, thereby
increasing the amount of endogenous IGFs that arevivo is associated with an up-regulation of type 1 IGF
receptors in the growth plate. available for binding to IGF receptors [48]. An alterna-
tive approach is IGFBP-selective IGF-I variants that areDuring longitudinal growth, two processes occur simul-
Kiepe et al: IGFBP action in growth plate chondrocytes 1599
11. Ulinski T, Mohan S, Kiepe D, et al: Serum insulin-like growthunable to bind to a certain inhibitory IGFBP with pre-
factor binding protein (IGFBP)-4 and IGFBP-5 in children with
served affinity for other IGFBPs [49]. The therapeutic chronic renal failure: Relationship to growth and glomerular filtra-
tion rate. Pediatr Nephrol 14:589–597, 2000potential of these novel peptides in disease conditions
12. Powell DR, Durham SK, Brewer ED, et al: Effects of chronicassociated with up-regulated inhibitory IGFBP levels,
renal failure and growth hormone on serum levels of insulin-like
such as renal failure, is currently being investigated. growth factor-binding protein-4 (IGFBP-4) and IGFBP-5 in chil-
dren: A report of the Southwest Pediatric Nephrology StudyIn summary, we have demonstrated that intact IGFBP-1,
Group. J Clin Endocrinol Metab 84:596–601, 1999IGFBP-2 and IGFBP-6 act exclusively as growth inhibi-
13. Jehle PM, Ostertag A, Schulten K, et al: Insulin-like growth
tors on IGF-dependent proliferation of growth plate chon- factor system components in hyperparathyroidism and renal osteo-
dystrophy. Kidney Int 57:423–436, 2000drocytes, whereas the biological activity of IGFBP-3 is
14. Blum WF, Albertsson-Wikland K, Rosberg S, Ranke MB: Se-complex. It has an IGF-independent antiproliferative
rum levels of insulin-like growth factor I (IGF-I) and IGF binding
effect and also inhibits IGF-dependent chondrocyte pro- protein 3 reflect spontaneous growth hormone secretion. J Clin
Endocrinol Metab 76:1610–1616, 1993liferation under coincubation conditions. Under preincu-
15. Kiepe D, Andress DL, Mohan S, et al: Intact IGF-binding pro-bation conditions, however, IGFBP-3 enhances IGF-I-
tein-4 and -5 and their respective fragments isolated from chronic
responsiveness of growth plate chondrocytes by its ability renal failure serum differentially modulate IGF-I actions in cultured
growth plate chondrocytes. J Am Soc Nephrol 12:2400–2410, 2001to associate with the cell membrane, where it facilitates
16. Baxter RC: Insulin-like growth factor (IGF)-binding proteins:IGF-I receptor binding.
Interactions with IGFs and intrinsic bioactivities. Am J Physiol
Endocrinol Metab 278:E967–E976, 2000
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